Investigational New Drugs

, Volume 33, Issue 6, pp 1225–1231 | Cite as

A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors

  • Autumn J. McRee
  • Hanna K. Sanoff
  • Cheryl Carlson
  • Anastasia Ivanova
  • Bert H. O’Neil


Purpose The oral PI3K inhibitor BKM120 has been reported as safe and well tolerated in early phase clinical trials of advanced cancer patients. We performed a phase I trial of BKM120 plus mFOLFOX6 (5-FU/LV + oxaliplatin), a common chemotherapeutic backbone in GI malignancies, to establish the maximum tolerated dose (MTD) and characterize the safety and tolerability of the combination. Methods Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle. The study utilized a standard 3 + 3 dose escalation schema. Results A total of 17 patients received treatment with BKM120, 13 of which were evaluate for dose limited toxicity (DLT). The most common tumor types were colorectal cancer, cholangiocarcinoma, pancreatic cancer and hepatocellular carcinoma. DLT included grade 3 hyperglycemia, grade 3 AST/ALT elevation, grade 4 neutropenia and grade 4 thrombocytopenia. A total of 76 % of patients experienced treatment related grade 3/4 adverse events (AEs), the most common of which were neutropenia, fatigue, leukopenia, hyperglycemia and thrombocytopenia. One patient demonstrated an unconfirmed partial response and three patients had stable disease. Discussion The MTD of BKM120 in combination with standard doses of mFOLFOX6 was 40 mg daily, which is well below the 100 mg daily dose proven effective and tolerable both as a single agent and in combination with other chemotherapeutics. In addition, the regimen of BKM120 with mFOLFOX6 in patients with refractory solid tumors resulted in increased toxicity than would be expected from either the PI3K inhibitor or the chemotherapy backbone alone.


BKM120 PI3K pathway 5-fluorouracil Oxaliplatin Gastrointestinal malignancies 



The authors would like to acknowledge grant funding support for this project. Dr. McRee receives support from the UNC Calabresi K12 Career Development Grant 2K12CA120780-06. Dr. Sanoff receives support from the National Cancer Institute K07CA160722.

Compliance with ethical standards

Conflict of interest

Dr. Hanna Sanoff has received research funding from Novartis. The remaining authors declare that they have no conflict of interest.


  1. 1.
    Brown KK, Toker A (2015) The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep 7:13PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMedGoogle Scholar
  3. 3.
    Cai X et al. (2015) Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002. Onco Targets Ther 8:877–883PubMedCentralPubMedGoogle Scholar
  4. 4.
    Cheng HB et al. (2015) Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedeberg's Arch Pharmacol 388(6):623–634CrossRefGoogle Scholar
  5. 5.
    Simioni C et al. (2015) The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 6:17147–17160CrossRefPubMedGoogle Scholar
  6. 6.
    Zheng YB et al. (2015) Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol 21(23):7197–7207PubMedCentralPubMedGoogle Scholar
  7. 7.
    Horiguchi H et al. (2014) Angiopoietin-like protein 2 renders colorectal cancer cells resistant to chemotherapy by activating spleen tyrosine kinase-phosphoinositide 3-kinase-dependent anti-apoptotic signaling. Cancer Sci 105(12):1550–1559PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Li B et al. (2014) Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget 5(22):11576–11587PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Ng SSW et al. (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60(19):5451–5455PubMedGoogle Scholar
  10. 10.
    Bendell JC et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282–290CrossRefPubMedGoogle Scholar
  11. 11.
    Hyman DM et al. (2015) Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol 75(4):747–755CrossRefPubMedGoogle Scholar
  12. 12.
    Mayer IA et al. (2014) Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202–1209PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Zambrano CC, Schuler MH, Machiels J-PH, Hess D, Paz-Ares L, Awada A, von Moos R, Steeghs N, Ahnert JR, De Mesmaeker P, Richly H, Herremans C, Joerger M, Jaime JC, Alsina M, Baffert F, Demanse D, Duval V, Morozov A, Dirix L (2014) Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). J Clin Oncol 32(5s):abstract 627Google Scholar
  14. 14.
    Goldberg RM et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30CrossRefPubMedGoogle Scholar
  15. 15.
    Tournigand C et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237CrossRefPubMedGoogle Scholar
  16. 16.
    Feng JP et al. (2013) Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Color Dis 15(1):27–33CrossRefGoogle Scholar
  17. 17.
    Feng JP et al. (2010) Impact of 5-fluorouracil on glucose metabolism and pancreatic pathology in rats. Zhonghua Wei Chang Wai Ke Za Zhi 13(12):935–938PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Autumn J. McRee
    • 1
  • Hanna K. Sanoff
    • 1
  • Cheryl Carlson
    • 1
  • Anastasia Ivanova
    • 1
  • Bert H. O’Neil
    • 2
  1. 1.Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Indiana University Melvin and Bren Simon Cancer CenterIndianapolisUSA

Personalised recommendations